Berberine hydrochloride plus lifestyle intervention,
does it really help with Reduction of ¹H-MRS liver fat in adults with NAFLD?
research showsGrade C with 50 points. In an open-label 184-person trial, lifestyle plus berberine reduced ¹H-MRS liver fat by 52.7% versus 36.4% with lifestyle alone (P=.008), but it was secondary in the registry, attrition remains, and a 2026 placebo trial in diabetes-free obesity with MASLD found no liver-fat benefit.
ads claimThis cannot be expanded to cirrhosis prevention, histologic recovery, or benefit for every person with MASLD.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. Gastrointestinal adverse effects occurred; people with liver disease or diabetes medicines need review for hypoglycemia and interactions. Avoid in pregnancy, lactation, and infants.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine-hydrochloride.oral-addon.liver-fat-mrs.reduce.lifestyleSupplements and nutraceuticals > Berberine hydrochloride > Oral add-on > ¹H-MRS liver fat > Reduction claim > Lifestyle intervention
Bound to ¹H-MRS liver fat after 1.5 g/day plus lifestyle for 16 weeks; weight, enzymes, histology, and the different-dose/population 2026 contract are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine hydrochloride |
| Source or part used | Purified berberine hydrochloride; source plant unverified |
| Formulation or processing | Berberine hydrochloride tablets plus standardized lifestyle intervention |
| Route | Oral add-on |
| Dose | 500 mg three times daily (1.5 g/day) |
| Duration | 16 weeks |
| Population | Adults with NAFLD; diabetes composition as reported in the paper |
| Effect or condition | Lower ¹H-MRS liver fat |
| Primary endpoint | Relative change in ¹H-MRS hepatic fat content at 16 weeks |
| Comparator | Lifestyle intervention alone |
| Duplicate-detection key | Berberine hydrochloride|Berberine hydrochloride tablets plus standardized lifestyle intervention|Oral add-on|Adults with NAFLD; diabetes composition as reported in the paper|Lower ¹H-MRS liver fat|16 weeks |
What the research actually shows
The NCT00633282 paper and registry were checked against the null NCT05647915 trial.
Why this is classified as C (50)
Axes are S/R0/I2/EX/B2/CX. Liver fat was secondary in the registry, so it is not counted as a prespecified primary E+ success. One I2 strength plus surrogate status, conflict, and attrition yield C/50.
Counterpoint. A 337-person 2026 trial found no liver-fat benefit from 1 g/day versus placebo (between-group 0.9 percentage points, 97.5% CI -0.4 to 2.1). The contract differs, but the directional conflict is retained.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R0 | Trials conflict in direction |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 55 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
| Berberine for Metabolic Dysfunction-Associated Steatotic Liver Disease | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 337 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Berberine Hydrochloride Plus Lifestyle for NAFLD Liver Fat—A Positive 16-Week Trial, but a Larger 2026 Trial Under a Different Contract Was Null — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/berberine-hydrochloride-lifestyle-nafld-liver-fat-mrs/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.